Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

BRIEF-Actinogen Medical seeks trading halt

Published 30/12/2016, 09:25 am
BRIEF-Actinogen Medical seeks trading halt
ACW
-

Dec 30 (Reuters) - Actinogen Medical Ltd ACW.AX

* requests that its securities be placed into an immediate trading halt pending an announcement regarding actinogen medical's application to FDA

* application to fda to initiate its Xanadu phase ii clinical trial in us of xanamem in treatment of Alzheimer's disease. Source text for Eikon: ID:nASX44Z32w Further company coverage: ACW.AX

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.